vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and TripAdvisor, Inc. (TRIP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $411.0M, roughly 1.7× TripAdvisor, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -9.2%, a 28.3% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 0.0%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-122.0M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 2.0%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
Tripadvisor is an American company that operates online travel agencies, comparison shopping websites, and mobile apps with user-generated content.
MEDP vs TRIP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $411.0M |
| Net Profit | $135.1M | $-38.0M |
| Gross Margin | — | 91.5% |
| Operating Margin | 21.6% | -8.3% |
| Net Margin | 19.1% | -9.2% |
| Revenue YoY | 32.0% | 0.0% |
| Net Profit YoY | 15.5% | -3900.0% |
| EPS (diluted) | $4.65 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $411.0M | ||
| Q3 25 | $659.9M | $553.0M | ||
| Q2 25 | $603.3M | $529.0M | ||
| Q1 25 | $558.6M | $398.0M | ||
| Q4 24 | $536.6M | $411.0M | ||
| Q3 24 | $533.3M | $532.0M | ||
| Q2 24 | $528.1M | $497.0M | ||
| Q1 24 | $511.0M | $395.0M |
| Q4 25 | $135.1M | $-38.0M | ||
| Q3 25 | $111.1M | $53.0M | ||
| Q2 25 | $90.3M | $36.0M | ||
| Q1 25 | $114.6M | $-11.0M | ||
| Q4 24 | $117.0M | $1.0M | ||
| Q3 24 | $96.4M | $39.0M | ||
| Q2 24 | $88.4M | $24.0M | ||
| Q1 24 | $102.6M | $-59.0M |
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 92.6% | ||
| Q2 25 | — | 92.1% | ||
| Q1 25 | — | 93.2% | ||
| Q4 24 | — | 93.4% | ||
| Q3 24 | — | 92.5% | ||
| Q2 24 | — | 92.8% | ||
| Q1 24 | — | 93.7% |
| Q4 25 | 21.6% | -8.3% | ||
| Q3 25 | 21.5% | 12.7% | ||
| Q2 25 | 20.9% | 11.2% | ||
| Q1 25 | 20.3% | -3.8% | ||
| Q4 24 | 23.4% | 0.2% | ||
| Q3 24 | 21.1% | 13.2% | ||
| Q2 24 | 19.9% | 7.2% | ||
| Q1 24 | 20.4% | -3.8% |
| Q4 25 | 19.1% | -9.2% | ||
| Q3 25 | 16.8% | 9.6% | ||
| Q2 25 | 15.0% | 6.8% | ||
| Q1 25 | 20.5% | -2.8% | ||
| Q4 24 | 21.8% | 0.2% | ||
| Q3 24 | 18.1% | 7.3% | ||
| Q2 24 | 16.7% | 4.8% | ||
| Q1 24 | 20.1% | -14.9% |
| Q4 25 | $4.65 | $-0.32 | ||
| Q3 25 | $3.86 | $0.43 | ||
| Q2 25 | $3.10 | $0.28 | ||
| Q1 25 | $3.67 | $-0.08 | ||
| Q4 24 | $3.67 | $0.03 | ||
| Q3 24 | $3.01 | $0.27 | ||
| Q2 24 | $2.75 | $0.17 | ||
| Q1 24 | $3.20 | $-0.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $1.0B |
| Total DebtLower is stronger | — | $819.0M |
| Stockholders' EquityBook value | $459.1M | $645.0M |
| Total Assets | $2.0B | $2.6B |
| Debt / EquityLower = less leverage | — | 1.27× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $1.0B | ||
| Q3 25 | $285.4M | $1.2B | ||
| Q2 25 | $46.3M | $1.2B | ||
| Q1 25 | $441.4M | $1.2B | ||
| Q4 24 | $669.4M | $1.1B | ||
| Q3 24 | $656.9M | $1.1B | ||
| Q2 24 | $510.9M | $1.2B | ||
| Q1 24 | $407.0M | $1.2B |
| Q4 25 | — | $819.0M | ||
| Q3 25 | — | $821.0M | ||
| Q2 25 | — | $822.0M | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | $831.0M | ||
| Q3 24 | — | $832.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $459.1M | $645.0M | ||
| Q3 25 | $293.6M | $707.0M | ||
| Q2 25 | $172.4M | $627.0M | ||
| Q1 25 | $593.6M | $643.0M | ||
| Q4 24 | $825.5M | $943.0M | ||
| Q3 24 | $881.4M | $944.0M | ||
| Q2 24 | $763.6M | $857.0M | ||
| Q1 24 | $671.5M | $825.0M |
| Q4 25 | $2.0B | $2.6B | ||
| Q3 25 | $1.8B | $2.8B | ||
| Q2 25 | $1.6B | $2.9B | ||
| Q1 25 | $1.9B | $2.8B | ||
| Q4 24 | $2.1B | $2.6B | ||
| Q3 24 | $2.1B | $2.7B | ||
| Q2 24 | $1.9B | $2.8B | ||
| Q1 24 | $1.8B | $2.7B |
| Q4 25 | — | 1.27× | ||
| Q3 25 | — | 1.16× | ||
| Q2 25 | — | 1.31× | ||
| Q1 25 | — | 1.81× | ||
| Q4 24 | — | 0.88× | ||
| Q3 24 | — | 0.88× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $-103.0M |
| Free Cash FlowOCF − Capex | $188.1M | $-122.0M |
| FCF MarginFCF / Revenue | 26.6% | -29.7% |
| Capex IntensityCapex / Revenue | 0.6% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $163.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $-103.0M | ||
| Q3 25 | $246.2M | $44.0M | ||
| Q2 25 | $148.5M | $202.0M | ||
| Q1 25 | $125.8M | $102.0M | ||
| Q4 24 | $190.7M | $-3.0M | ||
| Q3 24 | $149.1M | $-43.0M | ||
| Q2 24 | $116.4M | $51.0M | ||
| Q1 24 | $152.7M | $139.0M |
| Q4 25 | $188.1M | $-122.0M | ||
| Q3 25 | $235.5M | $25.0M | ||
| Q2 25 | $142.4M | $177.0M | ||
| Q1 25 | $115.8M | $83.0M | ||
| Q4 24 | $183.0M | $-26.0M | ||
| Q3 24 | $138.5M | $-63.0M | ||
| Q2 24 | $103.5M | $36.0M | ||
| Q1 24 | $147.2M | $123.0M |
| Q4 25 | 26.6% | -29.7% | ||
| Q3 25 | 35.7% | 4.5% | ||
| Q2 25 | 23.6% | 33.5% | ||
| Q1 25 | 20.7% | 20.9% | ||
| Q4 24 | 34.1% | -6.3% | ||
| Q3 24 | 26.0% | -11.8% | ||
| Q2 24 | 19.6% | 7.2% | ||
| Q1 24 | 28.8% | 31.1% |
| Q4 25 | 0.6% | 4.6% | ||
| Q3 25 | 1.6% | 3.4% | ||
| Q2 25 | 1.0% | 4.7% | ||
| Q1 25 | 1.8% | 4.8% | ||
| Q4 24 | 1.4% | 5.6% | ||
| Q3 24 | 2.0% | 3.8% | ||
| Q2 24 | 2.4% | 3.0% | ||
| Q1 24 | 1.1% | 4.1% |
| Q4 25 | 1.43× | — | ||
| Q3 25 | 2.22× | 0.83× | ||
| Q2 25 | 1.65× | 5.61× | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.63× | -3.00× | ||
| Q3 24 | 1.55× | -1.10× | ||
| Q2 24 | 1.32× | 2.13× | ||
| Q1 24 | 1.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
TRIP
| Third Party | $327.0M | 80% |
| The Fork | $58.0M | 14% |
| Other | $26.0M | 6% |
